<DOC>
	<DOCNO>NCT00461006</DOCNO>
	<brief_summary>This 2 arm study compare effect aleglitazar Actos , add preexist oral antihyperglycemic therapy and/or diet exercise , renal function patient type 2 diabetes , normal mildly impaired renal function . Eligible patient randomize receive either aleglitazar 0.6mg p.o . Actos 45mg p.o . daily . Renal function efficacy parameter assess interval treatment period . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Comparison Effects Aleglitazar Actos Renal Function Patients With Type 2 Diabetes .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>adult patient , 1875 year age ; type 2 diabetes &gt; =1 month ; drug naive , receive stable oral antihyperglycemic medication ; HbA1c 6.510.0 % screening . type 1 diabetes ; current previous treatment insulin ; history renal disease diabetic nephropathy ; uncontrolled hypertension ; clinically significant cardiovascular disease ; Congestive heart failure ( CHF ) New York Heart Association ( NYHA ) 34 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>